Pritumumab is under clinical development by Nascent Biotech and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 81% phase transition success rate (PTSR) ...
Since smoking can modify proteins by carbamylation (formation of homocitrulline), this study was conducted to investigate these effects on vimentin in animal models and RA. Methods The efficiency of ...
Other intermediate filaments are distributed more widely. For example, vimentin filaments are found in a broad range of cell types and frequently colocalize with microtubules. Similarly ...
Then sections were stained and photographed under a microscope (DFC310 FX, Leica, Germany). For immunofluorescence staining, rabbit anti-E-cadherin or anti-Vimentin antibodies (1:200 dilution; ...
与其他科室人来人往的场景不同,郴州市第四人民医院的这个科室没有患者,只有少数身穿白大褂的医生和技术员。他们或手拿着切片和报告进进出出,或端坐在显微镜前一丝不苟观察组织切片。而他们发出的病理报告,对于病人的诊断和治疗却起着决定性作用。这里,就是医院的病 ...
胃癌是我国最常见的恶性肿瘤之一,晚期胃癌五年生存率不足10%。胃癌的药物治疗主要包括化疗、分子靶向治疗及免疫检查点抑制剂等。人们常说“对症下药”才能“药到病除”,那么应该如何诊断胃癌并制定针对性治疗方案?除规范详尽化病理诊断外,免疫组织化学(Immu ...
Increased vimentin immunoreactivity was observed in the vape alone group compared with control and vape nicotine. The correlation between vaping, interstitial cell responses, and cardiac remodeling ...
This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.
EsoGuard uses DNA bisulfite conversion, PCR amplification, and next-generation sequencing to determine the methylation status of 31 sites in the vimentin and cyclin A1 genes, which indicate Barrett's ...
An international conference focusing on the Hsp90 molecular chaperone was recently held in Seeon, Germany. The program provided a current synopsis on a wide array of topics, including structural ...
This valuable manuscript provides an interesting account documenting the role of resident CD56(br) NK cells in driving interaction with dendritic cells that attract CD8+ T cells to the pancreas cancer ...